Disease · MONDO_0017594

indolent B-cell non-Hodgkin lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. indolent B-cell non-Hodgkin lymphoma. Diseases, record MONDO_0017594. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0017594

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: indolent B-cell non-Hodgkin lymphoma; Open Targets
Open Targets ID: MONDO_0017594; Open Targets
Other names: indolent B-cell NHL; Open Targets
NCI Thesaurus: C171299; NCI Thesaurus
Orphanet: ORPHA:300842; Orphanet
Highest stage of its drugs: Phase 3, for 9 of its 27 drugs, from ClinicalTrials.gov; Open Targets

Drugs27

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RITUXIMAB	CHEMBL1201576	Antibody	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
BENDAMUSTINE	CHEMBL487253	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
COPANLISIB	CHEMBL3218576	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
IBRUTINIB	CHEMBL1873475	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
OFATUMUMAB	CHEMBL1201836	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BORTEZOMIB	CHEMBL325041	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 27

See all 27 drugs

Targets82

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
MS4A1	B-lymphocyte antigen CD20	3	B-lymphocyte antigen CD20 binding agent	Phase 3	https://conductscience.org/library/genes/931	Drugs and targets
ADRM1	26S proteasome	2	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/11047	Drugs and targets
HDAC1	Histone deacetylase	2	Histone deacetylase 1 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/3065	Drugs and targets
HDAC2	Histone deacetylase	2	Histone deacetylase 2 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/3066	Drugs and targets
HDAC3	Histone deacetylase	2	Histone deacetylase 3 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/8841	Drugs and targets
HDAC6	Histone deacetylase	2	Histone deacetylase 6 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/10013	Drugs and targets
PIK3CD	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	2	PI3-kinase p110-delta subunit inhibitor	Phase 3	https://conductscience.org/library/genes/5293	Drugs and targets
PSMA1	26S proteasome	2	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5682	Drugs and targets
PSMA2	26S proteasome	2	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5683	Drugs and targets
PSMA3	26S proteasome	2	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5684	Drugs and targets

1 to 10 of 82

See all 82 targets

Trials26

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02626455	Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)	Phase 3	551	2024-12-11	Lymphoma, Non-Hodgkin	BENDAMUSTINE, COPANLISIB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02367040	Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)	Phase 3	458	2022-01-04	Lymphoma,Non-Hodgkin	COPANLISIB, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01077518	Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy	Phase 3	346	2020-03-27	Lymphoma, Follicular	BENDAMUSTINE, OFATUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00295932	Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma	Phase 1/2	79	2018-11-20	Leukemia, Lymphoma	BORTEZOMIB, CYCLOPHOSPHAMIDE, PREDNISONE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00875056	Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)	Phase 2	56	2020-10-29	Lymphoma	VORINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT00924326	CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma	Phase 1/2	43	2019-03-21	Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma, Mantle Cell	ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02339922	Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma	Phase 2	33	2026-03-05	Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia	IXAZOMIB CITRATE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT03133221	1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation	Phase 2	17	2024-09-19	Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma, B-cell Lymphoma, Transformed Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma	IDELALISIB	Its record names the disease	ClinicalTrials.gov
NCT02257242	Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma	Phase 1	11	2023-02-09	Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Small-Cell, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone	BENDAMUSTINE, RITUXIMAB, VINCRISTINE SULFATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02242045	Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)	Phase 1	6	2021-03-19	Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia), Marginal Zone Lymphoma	IDELALISIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 26

See all 26 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Copanlisib + Rituximab vs Placebo + Rituximab: deaths from any cause	99 of 307	50 of 146	453	NCT02367040	Trial comparisons
Copanlisib + Rituximab vs Placebo + Rituximab: serious adverse events	161 of 307	32 of 146	453	NCT02367040	Trial comparisons

Papers from its trials28

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33848462	RESULT	1	PubMed
32856068	RESULT	1	PubMed
28803861	RESULT	1	PubMed
28561902	RESULT	1	PubMed
28291388	RESULT	1	PubMed
28103725	RESULT	1	PubMed
25154820	RESULT	1	PubMed
24617454	RESULT	1	PubMed
24055823	RESULT	1	PubMed
23546520	RESULT	1	PubMed

1 to 10 of 28

See all 28 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0017594

GET https://conductscience.org/api/diseases/v1/MONDO_0017594/drugs?page=2

API reference For AI assistants